CLSD — Clearside Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00
- $97.88m
- $68.96m
- $8.23m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -30.8 | -18.2 | 0.376 | -32.9 | -32.5 |
Depreciation | |||||
Non-Cash Items | 4.79 | 3.79 | 4.06 | 8.2 | 13.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.3 | 1.12 | -15.3 | 11.2 | 0.72 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -27.1 | -13.1 | -10.7 | -13.4 | -18.1 |
Capital Expenditures | -0.025 | -0.055 | 0 | -0.246 | -1.78 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 33 | — | 0 | — | — |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 32.9 | -0.055 | 0 | -0.246 | -1.78 |
Financing Cash Flow Items | — | — | — | 30.6 | -1.35 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 8.7 | 7.87 | 23.8 | 31.3 | 0.414 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 14.6 | -5.31 | 13 | 17.7 | -19.5 |